Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, due in large part to a highly immunosuppressive tumour microenvironment. Although approximately 30% of PDAC tumours express PD L1, immune checkpoint inhibitors, most notably anti PD 1 therapies, have demonstrated minimal benefit in clinical settings. In a study published in Cancers, Holokai et al. (2020) employed a tiered translational strategy spanning mouse models and human systems. Their workflow combined orthotopic murine tumours with paired mouse- and patient-derived organoid cultures incorporating immune cells. This cross-species approach demonstrated that resistance to PD 1 inhibition is conserved between humans and mice and is primarily driven by suppressive myeloid cell populations rather than dysfunctional PD 1/PD L1 signalling. The study provides a robust preclinical framework for evaluating immune-based combination therapies prior to clinical translation.
Background
PDAC tumours evade anti-tumour immunity through a combination of tumour-intrinsic checkpoint signalling and the recruitment of extrinsic immunosuppressive cell types. While PD L1 expressed on tumour cells can inhibit CD8⁺ T-cell activity through engagement of PD 1, this pathway represents only one component of a broader network of immune suppression. Myeloid-derived suppressor cells (MDSCs), particularly the polymorphonuclear subset (PMN MDSCs), play a central role by limiting T-cell proliferation and effector function. These cells exert their suppressive effects via arginine depletion, production of reactive oxygen species, and other metabolic constraints. Accumulation of PMN MDSCs occurs early in pancreatic tumorigenesis and persists throughout disease progression. Elevated levels of these cells are consistently associated with diminished cytotoxic T-cell responses and worse clinical outcomes in both murine models and patient samples.
A dual-modality targeting approach
To simultaneously investigate checkpoint-mediated T-cell inhibition and myeloid-driven immune suppression in a physiologically relevant context, the authors established matched human and mouse organoid cultures co-cultured with immune cells. These platforms enabled direct testing of immunotherapeutic antibodies and real-time assessment of T-cell activation in the presence of suppressive myeloid populations. As part of this experimental setup, Bio X Cell’s InVivoPlus™ anti-mouse PD 1 antibody was administered to C57BL/6 mice seven days following orthotopic tumour implantation to inhibit PD 1 signalling in vivo. The results revealed that PD 1/PD L1 blockade alone failed to fully reinstate cytotoxic T cell function when PMN MDSCs remained active. In contrast, depletion of PMN MDSCs led to a marked enhancement of CD8⁺ T-cell activity, highlighting the therapeutic potential of combinatorial strategies. Collectively, these findings indicate that checkpoint resistance in PDAC reflects dominant myeloid-mediated immunosuppression rather than inadequate target engagement.
By leveraging parallel murine and human organoid systems, the investigators demonstrated consistent failure of checkpoint monotherapy across experimental platforms, reinforcing the translational relevance of their observations. This work underscores the limitations of traditional reductionist models, which often overlook critical immune interactions, and emphasises the importance of complex co-culture systems for accurately recapitulating the immune landscape of pancreatic cancer.
Antibody selection considerations for organoid-based immune models
As organoid-immune cell co-cultures gain traction for modelling tumour-immune interactions, the performance characteristics of antibodies used in these systems become increasingly important. To ensure experimental robustness and translational value, reagents should meet several essential criteria:
- Cross-system compatibility: reliable performance in both in vitro organoid cultures and in vivo models
- High purity: minimal endotoxin contamination and rigorous specificity testing
- Minimal additives: absence of carrier proteins or preservatives that could influence cell behaviour
- Transparent quality control: comprehensive validation and documentation standards
Bio X Cell’s InVivoPlus antibody portfolio is designed to meet these demands, offering reagents optimised for use in complex biological systems such as organoid–immune co-cultures. With antibodies targeting both human and murine antigens, these tools support translational workflows that integrate preclinical and clinical models. Each production lot undergoes stringent evaluation for purity, aggregation, and endotoxin content, ensuring consistency across high-sensitivity applications in immuno-oncology research.
Scientific and translational significance
The findings reported by Holokai and colleagues extend a growing body of literature that employs Bio X Cell antibodies to elucidate immune regulation within the tumour microenvironment. This organoid-based strategy enables deeper dissection of immune escape mechanisms and identifies actionable intervention points. As organoid technologies continue to increase in fidelity and complexity, access to validated, application-ready antibody reagents will remain critical for advancing both mechanistic understanding and clinical translation in cancer immunotherapy.
Learn more about Bio X Cell or contact our specialists to learn how Bio X Cell antibodies can support your research.
Reference
Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards SS, Woodson C, Steele N, Kuester R, Scott A, Khreiss M, Frankel T, Merchant J, Jenkins BJ, Wang J, Shroff RT, Ahmad SA, Zavros Y. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020 Dec 17;12(12):3816. doi: 10.3390/cancers12123816. PMID: 33348809; PMCID: PMC7766822.